Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 1, 2009

Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet

  • Chinese regulatory authorities approved Bayer Schering Pharma’s interferon beta-1b, Betaferon®, as a treatment for relapsing-remitting multiple sclerosis (MS). Bayer says it plans to launch the drug in the country by mid-2010.

    The company separately reported exercising its option as per an agreement inked in January with Micromet to develop a new BiTE antibody against solid tumors. The decision triggers a €5 million (about $7.55 million) payment to Micromet.

    Under the terms of the deal, the companies will jointly develop the BiTE candidate up to the end of Phase I trials, at which point Bayer will take over all further development and commercialization activities. Additionally, Micromet could receive milestones of up to €285 million (approximately $430.22 million) plus double-digit royalties on sales. The company will also have its R&D expenses reimbursed.

    BiTE antibodies are designed to direct the body's cytotoxic T cells against tumor cells. The molecules are designed such that one BiTE arm is specific for the T-cell receptor CD3 epitope, and the other is designed to bind to the target of interest. The resulting BiTE molecule induces an immunological synapse between the T cell and tumor cell in the same manner as that observed during physiological T-cell attacks, according to Micromet.

    This mediates the delivery of cytotoxic proteins directly into the tumor cell, which induces apoptosis. The company also suggests that unlike existing T-cell therapies, the BiTE approach does not require antigen presentation or other elements of T-cell recognition. It thus has the potential to circumvent immune-evasion mechanisms that tend to limit existing T-cell therapies.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »